• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

The Role of PPIs in Pediatric EoE Treatment

Opinion
Video

Elizabeth Spencer, MD, discusses the role of proton pump inhibitors (PPIs) in treatment of eosinophilic esophagitis (EoE) in pediatric patients.

This is a video synopsis/summary of an Insights involving Elizabeth Spencer, MD.

In this video, Spencer discusses the use of proton pump inhibitors (PPIs) to treat eosinophilic esophagitis (EoE) in pediatric patients. She notes that dietary therapy can be easier in young children since they are often already on specialized formula. PPIs may not be relied upon as heavily in infants since formula changes are socially acceptable and impactful. However, PPIs are very safe and effective in children.

The main safety concerns with PPIs are an increased risk of gastrointestinal infections in adults because stomach acid helps kill bacteria. Also in adults, there is a risk of bone breaks. However, Spencer states these risks have not been observed in pediatric populations. When using PPIs for EoE, the goal is to reach the minimal effective dose. This requires checking for the absence of eosinophils via repeated endoscopies while tapering the PPI dose over months. Many caregivers and patients find the frequent endoscopies frustrating.

Spencer discusses some alternatives under investigation to replace endoscopy for monitoring EoE, including transnasal endoscopy and devices to obtain esophageal samples less invasively. She notes that a blood test would be impactful if it could provide similar information to endoscopy. In conclusion, she emphasizes the importance of a multidisciplinary approach and providing patients options, such as transnasal endoscopy, which many centers now offer.

Video synopsis is AI-generated and reviewed by AJMC® editorial staff.

Related Videos
Video 2 - "Payer Needs and Strategies for Evaluating and Covering PDTs"
Video 1 - "Differentiating PDTs from Wellness Apps and Evaluating Efficacy"
Video 4 - "Oral SERDs in Development for ER+/HER2- Metastatic Breast Cancer"
Video 3 - "The Role of Oral SERDs in ER+/HER2- Metastatic Breast Cancer"
"Integrating New PAH Therapies into Clinical Practice"
"Clinical Evidence for Emerging PAH Therapies"
Video 13 - "Individualized Therapy for Specific Infections Associated with Bronchiectasis"
Video 11 - "Social Burden and Goals of Therapy for Patients with Bronchiectasis"
Video 15 - "Ensuring Fair Cardiovascular Care for All: Concluding Perspectives on Disparities and Inclusion"
Video 11 - "Social Burden and Goals of Therapy for Patients with Bronchiectasis"
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.